Class Action Lawsuit Says Makers of AndroDerm, Depo Testosterone Hid Risks of Cardiac Events, Stroke
April 18, 2014
DOCUMENTS
- Complaint
PHILADELPHIA — A Pennsylvania couple has filed a class action complaint against the makers of testosterone therapy drugs AndroDerm and Depo Testosterone, accusing them of aggressively marketing their products while failing to warn users of life-threatening side effects such as cardiac events and stroke.
In a complaint filed April 14 in the U.S. District Court for the Eastern District of Pennsylvania, Walter and Donna McGill accuse the drug makers of misrepresenting AndroDerm and Depo Testosterone as safe and effective treatment for hypogonadism or “low testosterone,” when, in fact, they can cause cardiac events, strokes and thrombolytic events.
Actavis Inc., Watson …
UPCOMING CONFERENCES
HarrisMartin’s Artificial Stone Silicosis Epidemic Litigation Conference
January 10, 2025 - Long Beach, CA
The Westin Long Beach